Biomedical Engineering Reference
In-Depth Information
10. Hauschild, A,
. (2009). Results of a phase III, randomized, placebo-
controlled study of sorafenib in combination with carboplatin and
paclitaxel as second-line treatment in patients with unresectable stage
III or stage IV melanoma,
et al
J Clin Oncol
.,
27
, pp. 2823-2830.
11. Hodi, FS,
. (2010). Improved survival with ipilimumab in patients
with metastatic melanoma,
et al
N Engl J Med
.,
363
, pp. 711-723.
12. Robert, C,
. (2011). Ipilimumab plus dacarbazine for previously
untreated metastatic melanoma,
et al
N Engl J Med
.,
364
, pp. 2517-2526.
13. Davis, H,
et al
. (2002). Mutations of the BRAF gene in human cancer,
Nature
,
417
, pp. 949-954.
14. Banerji, U,
. (2005). Phase I pharmacokinetic and pharmacodynamic
study of 17-allylamino-17-demethoxygeldanamycin in patients with
advanced malignancies,
et al
, pp. 4152-4161.
15. Robinson, MJ and Cobb, MH. (1997). Mitogen-activated protein kinase
pathways,
J Clin Oncol.,
23
Curr Opin Cell Biol
.,
9
, pp. 180-186.
16. Haluska, F,
. (2007). The RTK/RAS/BRAF/P13K Pathways
in Melanoma: Biology, Small Molecule Inhibitors, and Potential
Applications,
et al
, pp. 546-554.
17. Garnett M and Marais, R. (2004). Guilty as charged: B-RAF is a human
oncogene,
Semin Oncol
.,
34
Cancer Cell
,
6
, pp. 323-329.
18. Mason, CS,
. (1999). Serine and tyrosine phosphorylations
cooperate in Raf-1, but not B-RAF activation,
et al
EMBO J
.,
18
, pp. 2137-
2148.
19. Crews, CM,
. (1992). The primary structure of MEK, a protein
kinase that phosphorylates the ERK gene product,
et al
Science
,
258
, pp.
478-480.
20. Gardner, AM,
. (1994). MEK-1 phosphorylation by MEK kinase, Raf
and mitogen-activated protein kinase: analysis of phospho-peptides
and regulation of activity,
et al
Mol Biol Cell
.,
5
, pp. 193-201.
21. Kyriakis, JM,
et al
. (1992). Raf-1 activates MAP kinase-kinase,
Nature
,
, pp. 417-421.
22. Cantwell-Dorris, E,
358
. (2011). BRAF V600E: Implications for
Carcinogenesis and Molecular Therapy,
et al
Mol Cancer Ther
.,
10
, pp. 385-
394.
23. Conner, SR,
. (2003). Adhesion-dependent activation of the ERK
1/2 cascade is by-passed in melanoma cells,
et al
J Biol Chem.,
278
, pp.
34548-34554.
24. Dankort, D,
. (2009). Braf(V600E) cooperates with Pten loss to
induce metastatic melanoma,
et al
Nat Genet
.,
41
, pp. 544-552.
